1875 — BioDlink International Share News
0.000.00%
Last trade - 00:00- HK$2.59bn
- HK$2.70bn
- CNY747.65m
Brief: Tot Biopharm International Says Unit Entered Exclusive Promotion Service Agreement
Brief: Tot Biopharm International Agrees To Sell 1 Million Lumosa Shares At NTD36.5 Per Lumosa Share
Brief: TOT Biopharm International Gets Marketing Approval For Pusintin From NMPA
Brief: TOT Biopharm InternationalSays Unit, CR Pharma & Commercial And Suzhou Huayao Yuan Jointly Established JV
Brief: Tot Biopharm International Posts 9-Mths Net Loss RMB177.9 Mln Vs Loss Of RMB211.1 Mln
Brief: Tot Biopharm International Says HY Loss Attributable Rmb115 Million
Brief: Tot Biopharm International Says Drug Registration Approval For Temozolomide Capsule Obtained From NMPA
Brief: TOT Biopharm International Got Marketing Approval For Megestrol Acetate Oral Suspension From NMPA
Brief: Tot Biopharm International Posts Qtrly Total Comprehensive Loss RMB42.3 Mln
Brief: TOT Biopharm International Says FY Loss Attributable RMB288.5 Mln
Brief: TOT Biopharm International Says New Drug Application For Clinical Trial Of Tab014 Authorized By FDA
Brief: Tot Biopharm International 9-Month Net Loss RMB211.1 Mln
Brief: Tot Biopharm International Says Yeh-Huang, Chun-Ying Appointed Vice Chairman
Brief: TOT Biopharm International Posts HY Loss Attributable RMB 129.2 MLN
Brief: TOT Biopharm Says Predefined Primary Endpoint Of Randomized Phase III Clinical Trial Of Tab008 Recently Met
Brief: Tot Biopharm International Posts FY Revenue Rmb45.3 Mln, Up 16%